Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

August 2024

Investigation of plaque psoriasis relapse after secukinumab withdrawal in patients from two Phase III studies

Clin Exp Dermatol 2024;49:793–800 doi: 1093/ced/llad329

You R,

Following discontinuation of secukinumab 150mg or 300mg, a proportion of patients sustained low PASI with clear or almost clear skin despite being drug free for up to 2 years. Patients with a shorter disease duration were less likely to relapse, further supporting the hypothesis that earlier intervention with secukinumab may result in long-term control of moderate-to-severe psoriasis.

Keywords:

July 2024

The association between genetics and response to treatment with biologics in patients with psoriasis, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases: A systematic review and meta-analysis

Journal Reference: Int J Mol Sci 2024;25:5793 doi: 10.3390/ijms25115793

Skov L,

Genetic variants in TNFα, NLRP3, MYD88, and FcRγ genes were associated with a response to TNFi, when assessing several inflammatory diseases together. Al-Sofi et al. conducted a systematic review and meta-analysis on single nucleotide polymorphism (SNP) genetic markers and their response to biologics in psoriasis, PsA, RA, IBD, and across all chronic inflammatory diseases together.

Keywords:

Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the Phase 3, randomised SELECT-COMPARE study

RMD Open 2024;10:e004007 doi: 10.1136/rmdopen-2023-004007

Fleischmann R,

Swierkot J,

Penn SK,

Durez P,

Bessette L,

Bu X,

Khan N,

Li Y,

Peterfy CG,

Tanaka Y,

Mysler E

More RA patients on upadacitinib versus adalimumab achieved clinical remission, LDA, and DAS28 (CRP) <2.6. Radiographic progression was less with continuous upadacitinib versus continuous adalimumab. Upadacitinib showed similar safety to adalimumab, with higher incidences of HZ, lymphopenia, CPK elevation, hepatic disorder and nonmelanoma skin cancer.

Keywords:

Efficacy of brodalumab in moderate-to-severe plaque psoriasis after failure of previous biologic therapy: A phase 4, multicenter, open-label study

J Am Acad Dermatol 2024;90:1254–1256 doi 10.1016/j.jaad.2024.01.025

Papp K,

Maari C,

In this letter to the editor, Papp, et al. reported that brodalumab treatment in patients with psoriasis and an inadequate response to another biologic resulted in high rates of complete skin clearance with concurrent improvements in patient-reported outcomes after 26 weeks. The mean and median times to PASI 100 were 96.8 and 112 days, respectively.

Keywords:

February 2024

Effectiveness of Sequential Lines of Biologic and Targeted Small Molecule Drugs in Psoriatic Arthritis: A Systematic Review

Rheumatology (Oxford). 2024 Jan 18:keae006 doi: 10.1093/rheumatology/keae006 Epub ahead of print

Fahy C,

The authors found that there is a reduction in effectiveness of lines of bDMARDs after first-line in PsA, with inadequate data to determine response to tsDMARDs.

Keywords:

January 2024

Filgotinib Demonstrates Efficacy in Rheumatoid Arthritis Independent of Smoking Status: Post Hoc Analysis of Phase 3 Trials and Claims-Based Analysis)

Rheumatol Ther 2023;11(1):177–189 doi 10.1007/s40744-023-00619-0

Curtis JR,

Emery P,

Downie B,

Zhong Y,

Liu J,

Han L,

Hawtin RE,

Burmester GR

This post hoc analysis by Curtis, et al. found that current and former smokers were more likely to switch from an anti-TNF bDMARD to a different bDMARD or JAK inhibitor in comparison to non-smokers. They also found that DAS28(CRP) ≤3.2 achievement was significantly higher after filgotinib therapy regardless of smoking status in MTX-IR, bDMARD-IR, and MTX-naïve patients.